GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cocrystal Pharma COCP · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.11

+6.73%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Cocrystal Pharma

From its filings with the US Securities and Exchange Commission

SEC filings

Cocrystal Pharma is based in Bothell, Washington and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker COCP. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2020, it reported revenue of $2.0m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
12 Mar 2018
Employees
10
Head office
19805 N. CREEK PARKWAY, BOTHELL, WA, 98011
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Dr. Roger KornbergIndependent Chairman of the Board$209,972
  • Dr. Sam LeeCo-Chief Executive Officer, President, since 2014$680,859
  • Mr. James MartinCo-Chief Executive Officer, Chief Financial Officer$680,859
  • Dr. Phillip FrostIndependent Director$92,466
  • Mr. Fred HassanIndependent Director$50,498
  • Dr. Anthony JapourIndependent Director$80,716
  • Mr. Richard PfennigerIndependent Director$50,498
  • Mr. Steven RubinIndependent Director$115,644
  • Ms. Jody CainInvestor Relations, since 2021

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Cocrystal Pharma focuses on antiviral therapeutics for hepatitis C, influenza, and norovirus treatments.
  • The company uses computational methods to design drug candidates with cocrystal structural information.
  • CC-31244 is a pan-genotypic inhibitor for hepatitis C treatment targeting NS5B polymerase.

Weaknesses

  • Cocrystal Pharma has only 10 employees, limiting its operational capacity.
  • The company's IPO was in 2018, indicating limited market presence.
  • Cocrystal Pharma operates from Bothell, Washington, a location with less industry concentration.

Opportunities

  • The global antiviral market offers growth potential for hepatitis C and influenza treatments.
  • Cocrystal Pharma's computational methods could lead to new drug discoveries.
  • Norovirus treatments are an emerging area with unmet medical needs.

Threats

  • Cocrystal Pharma faces competition from established pharmaceutical companies in antiviral treatments.
  • The company's small size may hinder its ability to secure large-scale funding.
  • Regulatory approval processes for new antiviral drugs can be lengthy and costly.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.